Skip to content
Welcome To Our Store.
100,000+ Products for Home, Medical, Office & Classroom Needs
Search
Skip to product information
1 of 1

Lung Cancer: New Understandings and Therapies - Paperback

$194.38 USD
$194.38 USD
Sale Sold out
Shipping calculated at checkout.
In stock (100 units), ready to be shipped

Available Offers

Fast delivery available on most orders

Multiple secure payment options accepted

Secure checkout with
  • American Express
  • Apple Pay
  • Diners Club
  • Discover
  • Google Pay
  • Mastercard
  • PayPal
  • Shop Pay
  • Visa

Flight Range: Up to 1,000 meters (3,280 feet)

Maximum Speed: 45 kilometers per hour (28 miles per hour)

For all orders exceeding a value of 100USD shipping is offered for free.

Returns will be accepted for up to 10 days of Customer’s receipt or tracking number on unworn items. You, as a Customer, are obliged to inform us via email before you return the item.

Otherwise, standard shipping charges apply. Check out our delivery Terms & Conditions for more details.

View Product Details
Shopping cart
Product Product subtotal Quantity Price Product subtotal
Lung Cancer: New Understandings and Therapies - Paperback
Lung Cancer: New Understandings and Therapies - Paperback
Lung Cancer: New Understandings and Therapies - Paperback
$194.38/ea
$0.00
$194.38/ea $0.00

Product Description

by Anne C. Chiang (Editor), Roy S. Herbst (Editor)

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

Back Jacket

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

Author Biography

Anne Chiang is an Associate Professor at Yale University's School of Medicine and a member of the Yale Cancer Center's Developmental Therapeutics and Thoracic Oncology Programs. She serves as Chief Network Officer and the Deputy Chief Medical Officer at the Smilow Cancer Hospital at Yale. Chiang earned an MD from Weill Cornell Medical College, a Ph.D. in Molecular Genetics from Harvard University and an A.B. from Princeton University in Molecular Biology.

Roy Herbst is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale University's School of Medicine. He serves as Chief of Medical Oncology and the Associate Director for Translational Research at the Yale Cancer Center. Herbst earned his B.S. and M.S. degrees at Yale, his M.D. at Cornell University Medical College and his Ph.D. in Molecular Cell Biology at The Rockefeller University. He has authored more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters.

Number of Pages: 264
Dimensions: 0.57 x 9.21 x 6.14 IN
Illustrated: Yes
Publication Date: October 02, 2022
you might like